Johnson & Johnson announced a proposed settlement valued at as much as $5.5bn to resolve approximately 76,000 lawsuits in the United States alleging that its baby powder and other talc-containing products caused ovarian cancer. The settlement represents a significant step toward concluding a lengthy legal dispute that has affected the New Jersey-based company for years.
The healthcare firm will initially provide up to $3bn next year, with no additional payments required before 2028, according to the company’s statement. J&J emphasized that the agreement requires acceptance from legal representatives of 95% of ovarian cancer claimants in state and federal courts before finalization can occur.
Despite the settlement proposal, J&J has consistently maintained that the allegations against it are without merit and has denied that its talc-based products caused cancer. Erik Haas, the company’s vice president of litigation, stated that J&J was willing to settle to resolve the matter, while asserting that the company would have “ultimately prevailed with further litigation” based on its track record in court. He noted that the resolution would allow J&J to redirect its focus toward developing medicines and devices.
Lawsuits against the company over talc-based baby powder began as early as 2009, with claimants asserting that the products contained asbestos contamination. Talc is a naturally occurring mineral often found in seams near asbestos deposits. J&J has stated that studies demonstrate talc is safe and does not contain asbestos or cause cancer. In 2022, the company discontinued production of talc-based baby powder globally, transitioning to a cornstarch-based formula. Additionally, J&J’s former consumer health division, Kenvue, which was separated in 2022, maintains liability for Johnson’s baby powder sales outside North America.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI